Chris Bowden
YOU?
Author Swipe
A Systematic Qualitative Review of Parent Perceptions and Experiences of Augmentative and Alternative Communication for Their Autistic Children Open
Augmentative and alternative communication (AAC) can benefit autistic children. AAC should be integrated into daily life, especially parent–child interactions, as parents are often key communication partners. The aim of this qualitative sy…
The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design Open
Introduction Pyruvate kinase (PK) deficiency is a rare, under-recognised, hereditary condition that leads to chronic haemolytic anaemia and potentially serious secondary complications, such as iron overload, cholecystitis, pulmonary hypert…
Parent experiences of their children’s diagnosis with autism, attention deficit hyperactivity disorder, or both conditions Open
Purpose: A comparison of parents' experiences of getting a diagnosis for their child with autism, attention deficit hyperactivity disorder (ADHD) and both diagnoses can inform our understanding of common and unique themes across these neur…
Introduction Open
No abstract.
Ivosidenib in Isocitrate Dehydrogenase 1<i>–</i>Mutated Advanced Glioma Open
PURPOSE Diffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor grade is typically associated with contrast enhancement on magnetic resona…
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML Open
Isocitrate dehydrogenase (IDH) 1 and 2 mutations result in overproduction of D-2-hydroxyglutarate (2-HG) and impaired cellular differentiation. Ivosidenib, a targeted mutant IDH1 (mIDH1) enzyme inhibitor, can restore normal differentiation…
View article: Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency Open
The administration of mitapivat was associated with a rapid increase in the hemoglobin level in 50% of adults with pyruvate kinase deficiency, with a sustained response during a median follow-up of 29 months during the extension phase. Adv…
Vulture updates No 09 - September 2018 - Around the World of Vultures & VSG activities Open
Around the World of Vultures & VSG activitiesThis biannual newsletter of the IUCN Vulture Specialist Group mainly features updates by region but also mentions developments of VSG and we are aware that we still need to do much more.We now h…
PF426 GENOTYPE‐RESPONSE CORRELATION IN DRIVE PK, A PHASE 2 STUDY OF MITAPIVAT (AG‐348) IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY Open
Background: Pyruvate kinase (PK) deficiency is a congenital hemolytic anemia caused by mutations in the PKLR gene, leading to a deficiency of the glycolytic enzyme red cell PK (PK‐R). Mitapivat (AG‐348) is an oral, small‐molecule, alloster…
Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects Open
No ivosidenib dose adjustment is deemed necessary for Japanese subjects. High-fat meals should be avoided when ivosidenib is taken with food. When co-administered with strong CYP3A4 inhibitors, monitoring for QT interval prolongation (a pr…
Vulture updates - October 2017 - Around the World of Vultures & VSG activities Open
On 29 Nov 2016 in Mumbai, India, the co-chairs of the IUCN SSC VSG signed an agreement as co-operating partner with the CMS Raptors MoU.This formalises the VSG's support and commitment to implementation of the Raptors MoU in Africa and Eur…
Vulture updates - October 2016 - Around the World of Vultures & VSG activities Open
Around the World of Vultures & VSG activitiesUpdates include the latest on the CMS Multi-Species Action plan, the upcoming Africa meeting, further poisoning incidents, NSAIDs in Asia and elsewhere. The CMS Africa-Eurasian Vulture Multi-spe…
IUCN Species Survival Commission: Vulture Specialist Group Open
The IUCN SSC Vulture Specialist Group aims to advocate and create greater awareness of the plight of vultures
ACTR-46. AG-120, A FIRST-IN-class MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION Open
INTRODUCTION: Isocitrate dehydrogenase 1/2 (IDH1/2) mutations occur in >70% of low-grade gliomas (LGG) and lead to an altered metabolic state associated with production of D-2-hydroxyglutarate (2-HG), resulting in genetic/epigenetic dysreg…